Unusual Presentations of Metastatic Prostate Carcinoma as Detected by anti-3 F-18 FACBC PET/CT

• Authors: Rianot Amzat, Emory University; Pooneh Taleghani, Emory University; Bital Savir Baruch, Emory University; Peter Nieh, Emory University; Viraj Master, Emory University; Raghuveer Halkar, Emory University; Melinda Lewis, Emory University; Michelle Faurot, Emory University; Leah M. Bellamy, Emory University; Mark Goodman, Emory University; David Schuster, Emory University
• Journal Title: Clinical Nuclear Medicine
• Volume: Volume 36, Number 9
• Publisher: Lippincott, Williams & Wilkins | 2011-09-01, Pages 800-802
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1097/RLU.0b013e318219b47e
• Subjects: Health Sciences, Pathology; Health Sciences, Radiology
• Keywords: Science & Technology; Life Sciences & Biomedicine; Radiology, Nuclear Medicine & Medical Imaging; anti-3 F-18 FACBC; prostate cancer; PET; ACID; CANCER

Abstract

Prostate carcinoma is the second most common cause of cancer-related mortality in males in the United States. The pattern of metastatic disease of prostate cancer is well recognized, frequently involving sclerotic bone lesions and abdominopelvic lymph nodes. Anti-3 F-18 FACBC acid is a synthetic amino acid analog positron emission tomography radiotracer with reported utility in the detection of prostate carcinoma. We present 2 cases of unusual presentations of prostate carcinoma, one with malignant ascites and omental implants and the other with lytic bone lesions detected with anti-3 F-18 FACBC acid.